Treatment with a 1 -adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536 men with LUTS who were treated with alfuzosin (10 or 15 mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound measurements at baseline and 3 months. Total prostate volume increased by 0.4 ml from baseline in placebo patients but decreased by À0.25 ml in the combined alfuzosin groups. Percentage change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms; percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months' treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment.
Introduction
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) include hesitancy and a weak urinary stream. These symptoms are related to hyperplasia of androgen-dependent glandular or stromal nodules surrounding the proximal urethra. 1 Dynamic manifestations of LUTS include increased frequency of urination, nocturia, and urgency, symptoms that are linked to an increase in smooth-muscle tone, predominantly in the capsule of the prostate and the bladder neck, resulting from stimulation of a 1 -adrenergic receptors in these tissues. 2 Pharmacologic blockade of a 1 -adrenergic receptors relaxes the smooth muscle of the prostate and bladder neck and improves symptoms in many patients with BPH. For this reason, a 1 -blockers are now considered first-line agents for the management of LUTS due to BPH. 3 Recent investigations of the molecular mechanisms underlying the therapeutic effect of the quinazolinebased a 1 -blockers doxazosin and terazosin have provided evidence that these drugs induce apoptosis (programmed cell death) in the prostatic glandular epithelium and stroma of patients with BPH after 3-36 months of treatment. 4, 5 Evidence of apoptosis has been associated with improvement in clinical parameters. Apoptosis of the prostate tissue induced by a 1 -blockers could hypothetically alter the size and shape of the prostate over time, reducing its volume or halting further growth, thereby conferring considerable benefit in the treatment of BPH. However, no systematic studies designed to test this hypothesis have been performed. Preliminary studies with a 1 -blockers that have followed patients for at least 1 year have not incorporated regularly scheduled ultrasound or magnetic resonance imaging measurements of the prostate. 4 Even with such measurements, subtle differences in prostate size may not be detected because of the recognized variability of transrectal ultrasound (TRUS) results from examiner to examiner and from day to day.
We recently reported the results of a pivotal trial demonstrating the efficacy and safety of once-daily extended-release alfuzosin in the treatment of LUTS. 6 In this trial, we also investigated whether 3 months' treatment with alfuzosin, in comparison with placebo, would induce changes in either the total or transition zone volume of the prostate. This article reports these findings.
Methods
A total of 536 men were enrolled into this placebocontrolled, double-blind study. Patients were randomized to receive alfuzosin 10 or 15 mg once daily for 3 months or placebo. The enrollment criteria were described in our previous report. 6 In brief, men 50 years of age or older were enrolled if they had a history of LUTS, an International Prostate Symptom Score (IPSS) of at least 13 points, a maximal urinary flow rate (Q max ) between 5 and 12 ml/s (with a voided volume of 150 ml or more), a residual urine volume of 350 ml or less, and a quality of life index of at least three points. Men were excluded if they had lower urinary tract disease or a history of previous prostate surgery. Concomitant use of medications that might alter the voiding pattern, or the presence of clinically relevant biochemical abnormalities, were additional criteria for exclusion. Patients with a serum prostate-specific antigen (PSA) value greater than 10 ng/ml were not eligible. If the serum PSA level was between 4 and 10 ng/ml, the patient could be enrolled if a diagnosis of prostate cancer could be excluded to the satisfaction of the investigator.
All patients underwent TRUS measurements of prostate volume at baseline and following 3 months of therapy. The designated principle investigator at each of the 29 investigator sites performed each of the measurements. These investigators were all carefully trained in a standardized method of assessing prostate volume by TRUS. 7 Each took part in a 1-h lecture explaining the techniques of measurement of the prostate; the instruction included a teaching videotape as well as printed materials explaining the specific techniques to be utilized. The investigators were also given a copy of the videotape and asked to review it immediately prior to performing each examination. The training efforts were designed to increase the patient-to-patient and dayto-day reliability of the TRUS measurement of total prostate volume and transition zone volume.
The ellipse volume formula reference was used for all measurements, rather than the volume calculation from different ultrasound instruments. 7 Statistical analyses and graphing were performed using SigmaStat and SigmaPlot as well as SPSS vs 11.0. Baseline data distributions were described by mean and standard deviation. All tests performed were two-tailed using an alpha of 0.05 and accepting a P-value of o0.05 as significant. If not specified specifically, the P-values were 40.05 and thus not significant. Nonparametric data were compared using the Mann-Whitney U-test. Box and whisker plot were shown with mean, medians, 75% CI as boxes, 90% CI as whiskers and outliers.
Results
Baseline characteristics of the patients participating in the trial are shown in Table 1 . These patients represented a typical BPH patient population, having a mean IPSS score of 18.2 points, a mean quality-of-life score of 3.7, a mean total prostate volume ranging from 36.6 to 40.4 ml, and a transition zone volume ranging from 16.2 to 18.4 ml in the three arms of the trial. Table 2 shows the results of the volume measurements for the placebo and the combined 10-and 15-mg alfuzosin groups. No separation of results for the two doses was required, as the two groups did not differ significantly either at baseline or during follow-up.
Total prostate volume increased by 0.4 ml from baseline to 3 months in the placebo group, but decreased by 0.25 ml in the combined alfuzosin groups. The 80% bound fraction (i.e., the variability that encompasses 80% of all observations) was À7.5 to þ 8.9 ml in the placebo group and À8.8 to þ 8.3 ml in the alfuzosin group. The percent differences in total prostate volume from baseline to 3 months were similar in the placebo and alfuzosin groups ( Table 2 ).
The differences in transition zone volumes from baseline to 3 months were similar to those observed for total prostate volume, although they were smaller in the placebo group because of smaller transition 3 month volumes at baseline. Statistical analysis of the data showed that none of the differences between the placebo and the alfuzosin groups was statistically significant.
The main findings of the study are illustrated by box and whisker plots in Figure 1a and b, which show the changes in total prostate volume and transition zone volume, respectively, for all patients by treatment group. Both mean and median values for both total prostate volume and transition zone volume are very close to zero for all four groups: placebo, combined alfuzosin, alfuzosin 10 mg, and alfuzosin 15 mg. Figure 2a and b show individual measurements of total prostate volume, at baseline and at 3 months, sorted in ascending order by total prostate volume. The smallest prostate was approximately 18 g. The majority of prostates weighed between 20 and 60 g, and a few weighed more than 60 g. In two patients, the total prostate volume appeared to increase markedly, from about 20 g to about 50 g in one patient and from about 50 g to about 80 g in the other. These two values may be considered as outliers resulting from technical errors in the performance of the measurements. Comparison of Figure 2a and b shows that the distribution of prostate volume at 3 months was extremely close to the distribution at baseline, with very few outliers. Figure By two-tailed nonparametric tests, all differences between placebo and alfuzosin were not significant. prior ejaculation. The important observation is that no systematic increase or decrease in total prostate volume or in transition zone volume was observed within the 3-month treatment period.
Discussion
In this carefully controlled study, all three treatment groups were well matched at baseline for characteristics typical in a BPH population and also for total prostate volumes and transition zone volumes specifically. We observed that the magnitude of change in total prostate volume at 3 months was not significantly different between the placebo and the alfuzosin groups. Nor was there a significant difference between the groups in the change in transition zone volume from baseline to 3 months. No correlation between detectable volume increases or decreases and prostate size at baseline (small, intermediate, or large) was observed; rather, the changes were random and were likely to be the result of measurement errors. We conclude, therefore, that 3 months' treatment with alfuzosin does not induce volume changes that can be measured by TRUS or that can be separated or distinguished from random variations observed in the placebo group and which are undoubtedly attributable to measurement errors, technique errors, or day-to-day variations. These findings suggest that, if apoptosis is in fact present in patients treated with alfuzosin, it is not measurable as a prostate volume change by TRUS after 3 months of treatment with 10-or 15-mg doses.
Although induction of apoptosis by alfuzosin was not tested in the clinical studies reported by Kyprianou et al. 4, 5, 8 the composition of alfuzosin as a quinazoline derivative suggests that it may induce similar apoptotic effects. 9 However, the fact that peak plasma concentrations of alfuzosin (0.032 mM) achieved in patients treated with the extended-release, once-daily formulation 10 were lower than those achieved in patients treated with doxazosin (B0.146 mM) 11 or terazosin (B0.198 mM) 12 raises the possibility that apoptosis may not be a feature of treatment with alfuzosin, despite equivalent symptom improvement. Only direct identification of apoptotic cells in prostate tissue biopsy samples obtained from patients treated with alfuzosin is likely to show definitively whether apoptosis is associated with symptom relief. Tamsulosin, another a 1 -blocker, does not induce apoptosis in prostate cells in vitro. 13 However, prostate tissue from tamsulosin-treated patients likewise has not been examined for the presence of apoptotic cells after several months of treatment, leaving open the possibility that clinical observations of apoptosis in the prostates of a 1 -blocker-treated patients may differ from those in isolated prostate cells in vitro.
The present trial with alfuzosin is ongoing. Analysis of follow-up data at 12 and 24 months will be instrumental in determining whether long-term treatment has any impact on volume changes in patients treated with this particular a 1 -blocker. a 1 -blocker treatment does not affect prostate volume CG Roehrborn
